The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Using validated next-generation techniques for monitoring MRD in multiple myeloma
Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain, urges hematologists and oncologists interested in monitoring MRD in patients with multiple myeloma to only use validated, optimised next-generation techniques that have been recommended by the International Myeloma Working Group. Either NGS by Adaptive, the commercial vendor, or next-generation flow. Bruno discusses the availability of these techniques and the factors to consider when deciding which to use.
